<DOC>
	<DOCNO>NCT01358942</DOCNO>
	<brief_summary>This prospective observational study evaluate evolution lung cancer relate symptom correlation disease control rate ( complete response , partial response stable disease ) patient non-small cell lung cancer initiate first-line treatment standard platinum-based chemotherapy without Avastin ( bevacizumab ) . Data collect patient baseline 4-6 cycle chemotherapy .</brief_summary>
	<brief_title>An Observational Study Lung Cancer Related Symptoms Disease Control Rate Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With Without Avastin ( Bevacizumab )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm nonsmall cell lung cancer Initiating firstline treatment standard platinumbased chemotherapy , without bevacizumab Contraindications use platinumbased chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>